Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura

      This paper is only available as a PDF. To read, Please Download here.


      To define response to therapy and ultimate outcome of adults with idiopathic thrombocytopenic purpura (ITP).

      Patients and methods

      We retrospectively analyzed patients with FTP diagnosed between 1978 and 1988, and reexamined them between June 1992 and March 1993. Data from 208 cases were collected. Median patient age was 44 years (range 14 to 78) at the time of diagnosis, and 51 years (range 19 to 86) at reexamination. Length of follow-up ranged from 48 to 151 months (median 92) and was longer than 10 years in 26 patients (12.5%). Reexamination included a careful interview, physical examination, complete blood count, screening for HIV infection, determination of platelet-bound IgG, and, in persistently thrombocytopenic patients, autoimmunity markers and routine laboratory investigations.


      A total of 121 patients with fewer than 50 × 109 platelets per liter received an initial treatment with prednisone (PDN) at a dosage of 1 mg/kg of body weight for 1 month. Refractory or relapsed cases underwent splenectomy and/or other therapeutic modalities. In 87 patients with greater than 50 × 109 platelets per liter, no therapy was scheduled.
      An initial complete response to PDN was observed in 38.8% cases. A sustained complete remission (CR) lasting more than 6 months with no maintenance therapy was attained in 18.7%. At the time of last follow-up only 11 of these patients remained in CR.
      Sixty-three patients underwent splenectomy. Forty-seven (74.6%) had a CR, with 41 achieving a prolonged recovery (>6 months). Twelve other cases attained a sustained partial remission. Long-lasting recoveries were observed in 7 other cases following alternative treatments.
      Spontaneous remissions occurred in 8 of 87 untreated cases after observation periods of 6 months or more. Eleven deaths were recorded (6 women and 5 men, median age 73), but only 5 were attributable to thrombocytopenia. At last control, 43 patients were in complete remission and free from therapy, and 52 were still on therapy. Four thrombocytopenic patients had laboratory features and a clinical history consistent with an autoimmune disease.


      This analysis of ITP in adults suggests that splenectomy remains the most effective treatment. The majority of patients who undergo splenectomy can have a CR for many years, while only a minority of those who do not have this therapeutic modality or fail it are likely to attain similar results.
      The long-term prognosis of ITP is benign even in refractory cases. Spontaneous remissions can be observed in a significant percentage of untreated patients (about 9%). The development of overt autoimmune diseases is relatively uncommon. Particular attention should be given to the management of ITP in the elderly, where bleeding episodes of the central nervous system tend to occur more frequently.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Karpatkin S
        Autoimmune thrombocytopenic purpura.
        Seminars in Hematology. 1985; 22: 260-288
        • Baldini M
        Idiopathic thrombocytopenic purpura.
        NEJM. 1966; 274: 1245-1251
        • Manoharan A
        Treatment of refractory idiopathic thrombocytopenic purpura in adults.
        Br J Haematol. 1991; 79: 143-147
        • McVerry BA
        Management of idiopathic thrombocytopenic purpura in adults.
        Br J Haematol. 1985; 59: 203-208
        • Cortelazzo S
        • Finazzi G
        • Buelli M
        High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura.
        Blood. 1991; 77: 31-35
        • Picozzi VJ
        • Roeske WR
        • Creger WP
        Fate of therapy failures in adult idiopathic thrombocytopenic purpura.
        Am J Med. 1980; 69: 690-694
        • Pizzuto J
        • Ambriz R
        Therapeutic experience in 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the Cooperative Latin American Group on Haemostasis and Thrombosis.
        Blood. 1984; 64: 1179-1183
        • Jiji RM
        • Firozvi T
        • Spurling CL
        Chronic idiopathic thrombocytopenic purpura. Treatment with steroids and splenectomy.
        Arch Intern Med. 1973; 132: 380-383
        • Harris EN
        • Gharavi AE
        • Hedge U
        • et al.
        Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.
        Br J Haematol. 1985; 59: 231-234
        • Dixon R
        • Rosse W
        • Ebbert L
        Quantitative determination of antibody in idiopathic thrombocytopenic purpura: correlation of serum and platelet-bound antibody with clinical response.
        NEJM. 1975; 292: 230-236
        • DiFino SM
        • Lachant NA
        • Kirshner JJ
        • Gottlieb AJ
        Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy.
        Am J Med. 1980; 69: 430-442
        • Thompson RC
        • Moore RA
        • Hess CE
        • et al.
        Idiopathic thrombocytopenic purpura: long-term results of treatment and the prognostic significance of response to corticosteroids.
        Arch Intern Med. 1972; 130: 730-737
        • Den Ottolander GJ
        • Gratama JW
        • De Koning J
        • Brand A
        Long-term follow-up study of 168 patients with immune thrombocytopenic purpura.
        Scand J Hematol. 1984; 32: 101-110
        • Jacobs P
        • Wood L
        • Dent DM
        Results of treatment in immune thrombocytopenia.
        Q J Med. 1986; 58: 153-159
        • Bellucci S
        • Charpak Y
        • Chastang C
        • Tobelem Cl
        Low doses vs conventional doses of corticoids in immune thrombocytopenic purpura (ITP) . Results of a randomized clinical trial in 160 children, 223 adults.
        Blood. 1988; 71: 1165-1170
        • Guthrie TH
        • Brannan DP
        • Prisant LM
        Idiopathic thrombocytopenic purpura in the older adult patient.
        Am J Med Sci. 1988; 296: 17-21
        • Meyers MC
        Results of treatment of 71 patients with idiopathic thrombocytopenic purpura.
        Am J Med Sci. 1961; 242: 295-302
        • Shashaty GG
        • Rath CE
        Idiopathic thrombocytopenic purpura in the elderly.
        Am J Med Sci. 1978; 276: 263-267
        • Berchtold P
        • McMillan R
        Therapy of chronic idiopathic thrombocytopenic purpura in adults.
        Blood. 1989; 74: 2309-2317
        • Finch SC
        • Castro O
        • Cooper M
        • et al.
        Immunosuppressive therapy of chronic idiopathic thrombocytopenic purpura.
        Am J Med. 1974; 56: 4-12
      1. Ahn YS, Mylvaganam R, Garcia RO, et al. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med. 107:177–183.

        • Harris EN
        • Gharavi AE
        • Hughes GRV
        Anti-phospholipid antibodies.
        Clin Rheum Dis. 1985; 11: 591-596
        • Kernoff LM
        • Malan E
        Platelet antibody levels do not correlate with response to therapy in idiopathic thrombocytopenic purpura.
        Br J Haematol. 1983; 53: 559-562
        • Rosse WF
        Treatment of chronic immune thrombocytopenia.
        Clinics in Haematology. 1983; 12: 267-284
        • Berchtold P
        • Wenger M
        Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment.
        Blood. 1993; 81: 1246-1250
        • Fujisawa K
        • Tani P
        • Piro L
        • McMillan R
        The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura.
        Blood. 1993; 81: 2872-2877